// App-Quantinova.ai

TPS224 : Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).

Researchers

Presenter

  • Kanwal Pratap Singh Raghav

Principal Investigators

  • Takayuki Yoshino

  • Rosine Guimbaud

  • Ian Chau

  • Marc Van Den Eynde

  • Joan Maurel

  • Jeanne Tie

  • Tae Won Kim

  • Kun-Huei Yeh

  • Daniel Barrios

  • Kojiro Kobayashi

  • Emarjola Bako

  • Mehreteab Aregay

  • Gerold Meinhardt

  • Salvatore Siena

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • National Cancer Center, EPOC, Chiba, Japan

  • CHU Toulouse, Toulouse, France

  • The Royal Marsden Hospital, London, United Kingdom

  • Cliniques Universitaires Saint-Luc, UCL, Brussels, MN, Belgium

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Asan Medical Center, Seoul, South Korea

  • National Taiwan University Hospital, Taipei City, Taiwan

  • Daiichi Sankyo, Basking Ridge, NJ

  • Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Universita degli Studi di Milano, Milan, Italy

Locations

  • United States

  • Japan

  • France

  • United Kingdom

  • Belgium

  • Spain

  • Australia

  • Republic of South Korea

  • Taiwan

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

  • Oncology (ONC)

Disease

  • Colorectal Cancer

  • Solid malignancies

Biomarkers

  • Programmed cell death protein 1

  • Programmed death-ligand 1

Drug/Treatment

  • Trastuzumab

  • CRC02

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Double Blind/Blinded

  • Multiple Arm

  • Multicenteric

Phase

  • II

Study Id's

  • NCT04744831

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved